Vulnerability found in immunotherapy-resistant triple-negative breast cancer
Vanderbilt researchers, including Hematology and Oncology Drs. Justin Balko, Brian Lehmann and Vandana Abramson, have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.